Literature DB >> 34712004

Privacy and Confidentiality Considerations for Collecting HIV Risk Network Data among Men who Have Sex with Men and Implications for Constructing Valid Risk Networks.

Abby E Rudolph1,2, April M Young3,4.   

Abstract

Studies aiming to construct risk networks have historically collected network members' names, demographic characteristics and relational data (i.e., type, strength, duration, frequency of interaction, and HIV-related risk behaviors between the pair). Due to difficulties in constructing risk networks stemming from partner anonymity and the use of nicknames, some studies also collect network members' screen names, phone numbers, physical attributes, and scars/tattoos to assist with entity resolution. In-depth interviews with 20 men who have sex with men and transgender women in Kentucky assessed privacy/confidentiality concerns as well as accuracy/recall issues associated with providing these details. Most preferred providing alters' nicknames/first names only or a first name with the first letter of the last name. Many perceived screen names, phone numbers, and scars/tattoos to be too personal/identifying. Willingness to provide more detailed information varied by relationship type/strength, which could influence the validity of the resulting network.

Entities:  

Keywords:  Confidentiality; Free-list; HIV; Men who have sex with men; Name generator; Qualitative; Sexually Transmitted Infections; Social Network Analysis; Sociometric network

Year:  2019        PMID: 34712004      PMCID: PMC8547314          DOI: 10.1016/j.socnet.2019.09.002

Source DB:  PubMed          Journal:  Soc Networks        ISSN: 0378-8733


  59 in total

1.  Network structural dynamics and infectious disease propagation.

Authors:  J J Potterat; R B Rothenberg; S Q Muth
Journal:  Int J STD AIDS       Date:  1999-03       Impact factor: 1.359

2.  Using social network and ethnographic tools to evaluate syphilis transmission.

Authors:  R B Rothenberg; C Sterk; K E Toomey; J J Potterat; D Johnson; M Schrader; S Hatch
Journal:  Sex Transm Dis       Date:  1998-03       Impact factor: 2.830

3.  Outcomes of a risk-reduction intervention with high-risk populations: the Harlem AIDS project.

Authors:  S Deren; W R Davis; M Beardsley; S Tortu; M Clatts
Journal:  AIDS Educ Prev       Date:  1995-10

4.  Effects of a HIV risk reduction education program among injection drug users in Puerto Rico.

Authors:  H M Colón; R R Robles; D Freeman; T Matos
Journal:  P R Health Sci J       Date:  1993-04       Impact factor: 0.705

5.  Using Network and Spatial Data to Better Target Overdose Prevention Strategies in Rural Appalachia.

Authors:  Abby E Rudolph; April M Young; Jennifer R Havens
Journal:  J Urban Health       Date:  2019-02       Impact factor: 3.671

6.  Social networks and the spread of infectious diseases: the AIDS example.

Authors:  A S Klovdahl
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

Review 7.  The network approach and interventions to prevent HIV among injection drug users.

Authors:  A Neaigus
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

Review 8.  Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis.

Authors:  Amy Medley; Caitlin Kennedy; Kevin O'Reilly; Michael Sweat
Journal:  AIDS Educ Prev       Date:  2009-06

9.  Social networks and infectious disease: the Colorado Springs Study.

Authors:  A S Klovdahl; J J Potterat; D E Woodhouse; J B Muth; S Q Muth; W W Darrow
Journal:  Soc Sci Med       Date:  1994-01       Impact factor: 4.634

10.  Efficacy of a Multi-level Intervention to Reduce Injecting and Sexual Risk Behaviors among HIV-Infected People Who Inject Drugs in Vietnam: A Four-Arm Randomized Controlled Trial.

Authors:  Vivian F Go; Constantine Frangakis; Nguyen Le Minh; Carl Latkin; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Carla Zelaya; Pham The Vu; David D Celentano; Vu Minh Quan
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.